Pantoprazole

Generic Name: Pantoprazole

Brand Names: Protonix, Somac Control, Tecta, Pantozol Control, Controloc Control

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅F_₂N_₃O_₄S

CAS Number: 102625-70-7

Unique Ingredient Identifier: D8TST4O562

Background: Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...

Indication: Pantoprazole Injection:

Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
...

Associated Conditions: Erosive Esophagitis, GERD With Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Zollinger-Ellison Syndrome, Conditions where a reduction of gastric acid secretion is required, Pathological hypersecretory conditions

Associated Therapies: -

Clinical Trials

Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)

Phase 4

Conditions: Acute Coronary Syndromes

Interventions: Drug: omeprazole
Drug: Pantoprazole

First Posted Date: 2012-11-28

Last Posted Date: 2012-11-28

Lead Sponsor: Yaling Han

Target Recruit Count: 620

Registration Number: NCT01735227

Locations: 🇨🇳
OPEN trail, Shenyang, Liaoning, China
🇨🇳
ShenyangNH, Shenyang, Liaoning, China

Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Pantoprazole

First Posted Date: 2012-08-01

Last Posted Date: 2012-08-01

Lead Sponsor: Ranbaxy Laboratories Limited

Target Recruit Count: 40

Registration Number: NCT01654718

Locations: 🇮🇳
Clinical Pharmacology Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India

Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Pantoprazole

First Posted Date: 2012-08-01

Last Posted Date: 2012-08-01

Lead Sponsor: Ranbaxy Laboratories Limited

Target Recruit Count: 80

Registration Number: NCT01654705

Locations: 🇮🇳
Clinical Pharmacology Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India

The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia

Phase 4

Conditions: Nonulcer Dyspepsia

Interventions: Drug: Folic Acid
Drug: Pantoprazol

First Posted Date: 2012-05-31

Last Posted Date: 2012-05-31

Lead Sponsor: Bezmialem Vakif University

Target Recruit Count: 200

Registration Number: NCT01608750

Locations: 🇹🇷
Bezmialem medical faculty, Istanbul, Turkey

Pantoprazole on Insulin Secretion in Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: placebo
Drug: Pantoprazole

First Posted Date: 2012-03-01

Last Posted Date: 2014-02-21

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 14

Registration Number: NCT01541735

Locations: 🇲🇽
Instituto Mexicano del Seguro Social. Hospital de Especialidades., Guadalajara, Jalisco, Mexico

Structured Non-operative Treatment of Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Other: Neuromuscular training (NEMEX-TJR)
Behavioral: Information
Drug: Paracetamol
Drug: Burana
Drug: Pantoprazole
Behavioral: Dietary counseling
Behavioral: Patient education
Other: Insoles

First Posted Date: 2012-02-17

Last Posted Date: 2017-10-16

Lead Sponsor: Northern Orthopaedic Division, Denmark

Target Recruit Count: 100

Registration Number: NCT01535001

Locations: 🇩🇰
Department of Occupational and Physiotherapy, Aalborg Hospital-Aarhus University Hospital, Aalborg, Denmark
🇩🇰
Vendsyssel Hospital, Frederikshavn, Frederikshavn, Denmark
🇩🇰
Farsoe Hospital, Farsø, Denmark

Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis

Not Applicable

Conditions: Hemochromatosis

Interventions: Drug: Pantoprazole

First Posted Date: 2012-02-02

Last Posted Date: 2012-02-02

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 48

Registration Number: NCT01524757

Locations: 🇧🇪
University hospital Gasthuisberg, Leuven, Limburg, Belgium
🇳🇱
Atrium MC Parkstad, Heerlen, Limburg, Netherlands
🇳🇱
Maastricht university medical center, Maastricht, Limburg, Netherlands

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: pantoprazole
Drug: Pradaxa, within 30 minutes after a meal
Drug: Pradaxa (dabigatran etexilate)

First Posted Date: 2011-12-16

Last Posted Date: 2015-10-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1067

Registration Number: NCT01493557

Locations: 🇺🇸
1160.128.1011 Boehringer Ingelheim Investigational Site, Kalispell, Montana, United States
🇺🇸
1160.128.1041 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇺🇸
1160.128.1068 Boehringer Ingelheim Investigational Site, Roswell, Georgia, United States

and more 100 locations

Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement

Not Applicable

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Other: Neuromuscular training (NEMEX-TJR)
Drug: Paracetamol
Drug: Burana
Drug: Pantoprazol
Behavioral: Dietary counseling
Behavioral: Patient education
Procedure: TKR
Other: Insoles

First Posted Date: 2011-08-05

Last Posted Date: 2017-10-16

Lead Sponsor: Northern Orthopaedic Division, Denmark

Target Recruit Count: 100

Registration Number: NCT01410409

Locations: 🇩🇰
Department of Occupational and Physiotherapy, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Vendsyssel Hospital, Frederikshavn, Frederikshavn, Denmark
🇩🇰
Farsoe Hospital, Farsø, Denmark

A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Pantoprazole
Drug: SCH 530348 (standard percentage)
Drug: SCH 530348 (high percentage)

First Posted Date: 2011-05-23

Last Posted Date: 2015-09-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 173

Registration Number: NCT01358344

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy